ASX cannabis shares stage a comeback after the March bear market

ASX cannabis shares are staging a comeback after the March share market correction.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX cannabis shares are staging a comeback after the depths of the March bear market. Auscann Group Holdings Ltd (ASX: AC8) shares are up over 15% this morning, and 57% from March lows. AusCann has now commenced clinical evaluation of its products.

Cann Group Ltd (ASX: CAN) shares have also recovered from March lows, up 50%, as the company brings its first products to market. 

AusCann commences clinical evaluation

This morning, AusCann announced the commencement of its first clinical evaluation. The phase 1 study will evaluate the pharmacokinetics of 2 formulations of an orally administered THC/CBD combination. Volunteers have been recruited, with 1 group to receive a 2.5mg dose and the second a 10mg dose. Dosing of the first subjects has been completed.

The study will provide information to inform dose selection and assist medical professionals in prescribing AusCann's hard shell capsules. AusCann CEO Ido Kenyon said, "we are very excited to be progressing this important study to provide evidence-based information to medical professionals about our unique hard shell capsule."

The study is expected to be completed this calendar year. It is the first of many studies planned by AusCann to better understand and prove the benefits of using controlled dose medicinal cannabis. 

Cann Group products ready for commercial release

Cann Group announced the first of its product formulations, dried cannabis flower and cannabis oil from Australian grown cannabis, was ready for distribution at the start of the month.

The company revised its strategy in January in response to demand-supply disruptions in the global medicinal cannabis market. The revised strategy focuses on initially meeting Australian demand as export markets continue to be developed. The Group has also reduced operating expenses including a reduction in headcount of 25% and elimination or deferment of $7 million in annualised costs. 

Cann Group is continuing to progress funding options for its Mildura facility. The company plans to proceed with the first stage of the facility which will have an annual capacity of 25,000kg of dried flower. The Board has advised that market volatility relating to COVID-19 impacts may delay a decision on funding until the end of the financial year. 

Cann Group believes it has sufficient working capital to support operations through the remainder of the financial year. It issued $8 million in convertible notes in February to provide working capital. The immediate priority remains securing funding for the Mildura facility. In the meantime, however, Cann Group is seeking to progress potential supply agreements with third parties in Australia and overseas. 

Should you invest $1,000 in Arcadium Lithium Plc right now?

Before you buy Arcadium Lithium Plc shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Arcadium Lithium Plc wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finally caught a break this Friday.

Read more »

A man sits nervously at his computer with his mouth resting against his hands clasped in front of him as he stares at the screen of his computer on a home desk.
Share Market News

It's official: US stock market enters correction

The S&P 500 is now down 10.13% from its most recent peak.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

Guess which ASX 200 share Bell Potter says could rocket 100%+

The broker thinks this share is seriously undervalued.

Read more »

Four people on the beach leap high into the air.
Share Gainers

4 ASX All Ords stocks shrugging off the looming 2025 market correction and charging higher

If the ASX All Ords enters a 2025 market correction, don’t blame these soaring stocks!

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Catalyst Metals, Droneshield, Liontown, and Northern Star shares are charging higher

These shares are ending the week with a bang. But why?

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Black Cat, CAR Group, Data#3, and Helia shares are falling today

These shares are ending the week in the red. But why?

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »